hydroxyurea has been researched along with HMN (Hereditary Motor Neuropathy) Proximal Type I in 4 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxyurea may enhance splice function and increase the number of nuclear 'gems', small nuclear organelles in which survival motor neuron protein concentrates." | 2.44 | Clinical trials in spinal muscular atrophy. ( Darras, BT; Kang, PB, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wadman, RI | 3 |
| van der Pol, WL | 2 |
| Bosboom, WM | 3 |
| Asselman, FL | 1 |
| van den Berg, LH | 3 |
| Iannaccone, ST | 3 |
| Vrancken, AF | 3 |
| Wokke, JH | 2 |
| Darras, BT | 1 |
| Kang, PB | 1 |
4 reviews available for hydroxyurea and HMN (Hereditary Motor Neuropathy) Proximal Type I
| Article | Year |
|---|---|
Drug treatment for spinal muscular atrophy types II and III.
Topics: Adolescent; Amines; Child; Child, Preschool; Creatine; Cyclohexanecarboxylic Acids; gamma-Aminobutyr | 2020 |
Drug treatment for spinal muscular atrophy types II and III.
Topics: Acetylcarnitine; Adolescent; Amines; Child; Child, Preschool; Creatine; Cyclohexanecarboxylic Acids; | 2011 |
Drug treatment for spinal muscular atrophy types II and III.
Topics: Acetylcarnitine; Adolescent; Amines; Child; Child, Preschool; Creatine; Cyclohexanecarboxylic Acids; | 2012 |
Clinical trials in spinal muscular atrophy.
Topics: Animals; Child; Clinical Trials as Topic; Cyclic AMP Response Element-Binding Protein; Enzyme Inhibi | 2007 |